Richard Weaver is the founder and CEO of XenoGesis. His clear scientific rationale, business direction, vision and entrepreneurial approach have seen XenoGesis consistently expand and grow to become the UK’s largest independent DMPK provider.
Richard set up the business in 2011, when he spotted a gap and opportunity in the market. XenoGesis now works with over 200 companies and Universities across the globe and has provided experimental data, advice and PK predictions on eight compounds that are now in the clinic.
The business has grown from three to nearly 40 employees in over nine years. In 2018, Richard led the move into state-of-the-art laboratories and offices at BioCity’s Discovery Building to provide the platform for future growth.
Richard gained a first-class honours degree in chemistry with awards for the best performance in every year, followed by a medicinal chemistry PhD with a Wellcome Trust scholarship at the University of Leicester and two subsequent postdoctoral positions at the Welsh School of Pharmacy. In 1997, Richard joined Astra Charnwood within Discovery DMPK, and progressed to Group and Project Leader at AstraZeneca.
